SBIR/STTR Research Award

Computer-based HIV Prevention for Seropositive Men

Award identifier 86f190279c555f939ccda346bfa0ee02ffb697349a95dc5cc48da435997d2803Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$696,719

Program and phase

SBIR · Phase I

Award year

2013

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Amplyx Pharmaceuticals, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
N4A8X52DCND5
Solicitation number
PA12-088
Topic code
NINDS

Research abstract

DESCRIPTION (provided by applicant): Cryptococcosis is a devastating opportunistic infection caused primarily by Cryptococcus neoformans. Cryptococcosis most often spreads to the brain, causing cryptococcal meningitis (CM), and is fatal if left untreated.CM is the AIDS-defining central nervous system (CNS) illness and occurs in 60-70% of HIV positive individuals worldwide. In sub-Saharan Africa, CM causes more than 500,000 annual deaths among HIV positive patients compared with 350,000 annual fatalities for tuberculosis in the overall population. CM presents with symptoms including severe nausea, headache due to inflammation of the meninges, altered mental status, and fever. Lack of access to the recommended first-line therapeutic combination of amphotericin B/flucytosine (AmB/flucytosine) is a key component of the high mortality rate in the developing world. Access in this setting is hindered by the need for hospital-based i.v. administration of these drugs which lack an oral formulation. Moreover, the mortality rate for HIV-infected acute CM patients is over 20% within 3 months after infection in North America, despite patient access to AmB/flucytosine. Fluconazole, an oral, fungistatic drug, is used after the initial treatment with AmB/flucytosine, and isoften used for months after induction therapy. Sales of Gilead's liposomal Ambisome B alone (not counting generic AmB) were 330 million in 2011 while sales of fluconazole exceeded 1 billion annually, prior to 2003. By employing a novel screen for fungicidal compounds, we identified several molecules that target C. neoformans Pkh2-02 kinase. Encouraged by preliminary data demonstrating that orally available Pkh2-02 kinase inhibitors combined with fluconazole have fungicidal activity, we plan to create a novel and efficacious treatment for CM. Aim 1. Employ initial library screening results and SAR to design a small library of Pkh2-02 inhibitors Aim 2. Screen and select compounds for antifungal activity against strains of C. neoformans as monotherapy and combined with fluconazole (FL) or posaconazole (POS), evaluate initial pk properties and cytotoxicity, and iterate library based on observed SAR. Aim 3. Iterate library as needed to generate an additional 40 compounds based on the Aim 2 results to refocus library and perform more detailed pk and pd screens. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Cryptococcal meningitis (CM) is the AIDS-defining illness for 60-70% of HIV positive individuals with an estimated worldwide occurrence of 1 million cases annually. CM is invariably fatal if left untreated and even with access to preferred therapeutics, the mortality rate is over 20%. There is a clear need for new, readily-available therapeutics to improve the treatment of this deadly disease.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

13 SBIR/STTR records share this UEI (2011–2017). Reported award amounts total $11,388,318. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.